Cognitive disorders have a broad differential diagnosis, and a precise, timely diagnosis is essential for personalized treatment and care. Currently, dementia diagnoses are often not further specified according to the underlying pathology and are frequently delayed by several years. However, with the upcoming disease-modifying treatments (DMTs) for AD, an accurate, pathology-driven (i.e., etiological) diagnosis will become necessary.
Blood-based biomarkers (BBMs) are promising tools for detecting Alzheimer's disease (AD), with current research showing high concordance with cerebrospinal fluid (CSF) biomarkers and amyloid PET imaging. However, it remains unclear how physicians would value the availability of BBMs for AD in routine clinical practice. The investigators hypothesize that BBMs will benefit both patients and physicians in the diagnostic process within a memory clinic setting.
This study aims to investigate clinical impact and diagnostic utility of blood-based biomarkers for AD in the diagnostic process of a memory clinic. The main objectives are to investigate change in diagnosis, diagnostic certainty and patient management, due to BBM results.
Patient presents in memory clinic with cognitive complaints.
The physician is concerned about underlying AD as etiology of the complaints.
Adequate fluency in Dutch to understand informed consent procedure.
Age under 55.
Previous biomarker-confirmed diagnosis of AD.
Alcohol or drug abuse to such an extent that treatment would be advisable.
Patient is incapacitated, and is not able to judge consequences of participation.
Alzheimercentrum Amsterdam
Lead sponsor
Davos Alzheimer's Collaborative
Collaborator
Quanterix Corporation (in kind)
Collaborator